ライフサイエンスコーパス: systemic vasculitis

1 of six eyes presenting with a PUK and proven systemic vasculitis.

2 tion in rheumatic diseases including SLE and systemic vasculitis.

3 ly reported but poorly understood paediatric systemic vasculitis.

4 involvement, and is more often a form of non-systemic vasculitis.

5 zing ocular signs as potential indicators of systemic vasculitis.

6 al blood eosinophilia and symptoms caused by systemic vasculitis.

7 granulomatosis with polyangiitis, a form of systemic vasculitis.

8 se features and treatments of these forms of systemic vasculitis.

9 e, and tolerable therapies for children with systemic vasculitis.

10 recommendations in the management of primary systemic vasculitis.

11 ease should be integral to the management of systemic vasculitis.

12 vascular morbidity for children with primary systemic vasculitis.

13 in finding other therapies to treat primary systemic vasculitis.

14 tis is defined within the context of primary systemic vasculitis.

15 the use of biologic agents as treatments for systemic vasculitis.

16 of endothelial injury during ANCA-associated systemic vasculitis.

17 i-neutrophil cytoplasmic antibody-associated systemic vasculitis.

18 (ANCA) are implicated in the pathogenesis of systemic vasculitis.

19 e response from tolerance to autoimmunity in systemic vasculitis.

20 (ANCA) are implicated in the pathogenesis of systemic vasculitis.

21 play an important role in clinical trials of systemic vasculitis.

22 dels have been proposed for various forms of systemic vasculitis.

23 of morbidity and mortality in patients with systemic vasculitis.

24 arious infectious syndromes in patients with systemic vasculitis.

25 und in the circulation of many patients with systemic vasculitis.

26 rkedly improved the outcome in patients with systemic vasculitis.

27 sa (PAN) has been used as a generic term for systemic vasculitis.

28 t not the ACR criteria for any other type of systemic vasculitis.

29 nuate the consequences of CCE like that with systemic vasculitis.

30 al tract, peripheral nerves, and skin due to systemic vasculitis.

31 mune disorders (1.32; 95% CI, 1.16-1.50) and systemic vasculitis (1.29; 95% CI, 1.16-1.44).

32 on included connective tissue disease (38%), systemic vasculitis (36%), and autoimmune cytopenia (22%

33 ), systemic autoimmune disorders (7472), and systemic vasculitis (6283) and in 373 851 matched contro

34 ovasculitis was significantly related to non-systemic vasculitis (71% versus 23%, odds ratio, 7.9; 95

35 tineutrophil cytoplasmic antibody-associated systemic vasculitis (AASV) as a model of systemic inflam

36 i-neutrophil cytoplasmic antibody-associated systemic vasculitis (AASV) as a model of systemic inflam

37 trophil cytoplasm antibody (ANCA)-associated systemic vasculitis (AASV) remain limited and hampered b

38 tineutrophil cytoplasmic antibody-associated systemic vasculitis (AASV), a disease not associated wit

39 They are common in patients with primary systemic vasculitis and are seen in vasculitis secondary

40 teinase-3 (PR3) antibodies in development of systemic vasculitis and granulomatosis with polyangiitis

41 periodontitis, inflammatory bowel diseases, systemic vasculitis and HIV infection, as well as chemot

42 tant role in vascular injury associated with systemic vasculitis and in models of autoantibody- and i

43 inicians should perform extended work-up for systemic vasculitis and keep a high index of suspicion f

44 rats induced marked autoantibody production, systemic vasculitis and lymphocytic infiltration of the

45 in 88% of patients with antibody-associated systemic vasculitis and permitted reduction in steroid d

46 ion underscores the importance to assess for systemic vasculitis and to maintain high suspicion for i

47 tinguish it from atherosclerotic AAA or from systemic vasculitis and to treat it with the appropriate

48 of agents commonly used in the treatment of systemic vasculitis, and 2) a framework for the diagnost

49 n important complication of several forms of systemic vasculitis, and it may result in significant mo

50 Autoimmune rheumatic diseases may present as systemic vasculitis, and systemic vasculitis may simulat

51 of this activity have long been attempted in systemic vasculitis, and, more recently, in atherosclero

52 cent developments in the nosology of primary systemic vasculitis are placed in the context of an hist

53 Systemic vasculitis associated with antineutrophil cytop

54 Systemic vasculitis associated with autoantibodies to ne

55 granulomatosis with polyangiitis (EGPA) is a systemic vasculitis associated with chronic rhinosinusit

56 tion of hepatitis C virus (HCV) infection is systemic vasculitis associated with type II cryoglobulin

57 The study cohort comprised 39 children with systemic vasculitis at various stages of disease activit

58 to an unselected cohort of 130 patients with systemic vasculitis attending a single district hospital

59 scopic polyangiitis is a subgroup of primary systemic vasculitis, but diagnostic problems remain with

60 tis, are the connective tissue disorders and systemic vasculitis, but systemic infections and maligna

61 e-phase reactant levels in the patients with systemic vasculitis, but there was a poor correlation ov

62 Systemic vasculitis, common forms of which include anti-

63 ents with a new diagnosis of ANCA-associated systemic vasculitis confirmed by renal biopsy and serum

64 Plasma from patients with active systemic vasculitis contained significantly higher numbe

65 e specific factors involved in thrombosis in systemic vasculitis could help explain the role of infla

66 is affecting the nervous system includes (1) Systemic vasculitis disorders (necrotizing arteritis of

67 expression on neutrophils from patients with systemic vasculitis, Fc gammaRIIIb is likely to play a c

68 Patients with clinically active SLE or systemic vasculitis had accelerated spontaneous death of

69 ments in the classification and treatment of systemic vasculitis have led the European League Against

70 Temporal arteritis, the most common form of systemic vasculitis in adults, is a panarteritis that ch

71 ell arteritis (GCA), the most common form of systemic vasculitis in adults, preferentially involves l

72 ayasu arteritis) are the most common form of systemic vasculitis in adults, they remain incompletely

73 iant cell arteritis (GCA) is the most common systemic vasculitis in elderly individuals.

74 AVTEs in systemic vasculitis, including monogenic forms of vascul

75 VDI scores for 100 patients with systemic vasculitis increased from initial presentation

76 Assessment of systemic vasculitis is an essential part of its manageme

77 ience with these agents for the treatment of systemic vasculitis is with antitumor necrosis factor ag

78 ene (previously known as CECR1) results in a systemic vasculitis known as deficiency of ADA2 (DADA2).

79 Current biomarkers of renal disease in systemic vasculitis lack predictive value and are insens

80 tis can occur in various conditions, such as systemic vasculitis like Anti-Neutrophil Cytoplasmic Ant

81 ry information suggesting that the impact of systemic vasculitis may be significant and far greater t

82 AECA in patients with SLE or systemic vasculitis may contribute to pathogenesis by in

83 ases may present as systemic vasculitis, and systemic vasculitis may simulate autoimmune rheumatic di

84 necrosis in the absence of overt evidence of systemic vasculitis, occurred in 3 patients.

85 och Schonlein Purpura (HSP) is the commonest systemic vasculitis of childhood typically presenting wi

86 Kawasaki disease is an acute systemic vasculitis of childhood.

87 Kawasaki disease is a systemic vasculitis of childhood; its etiology is unknow

88 Kawasaki disease (KD) is a self-limited, systemic vasculitis of children for which an infectious

89 MC clinical manifestations are determined by systemic vasculitis of low/medium sized vessels (mixed c

90 saki disease is an acute febrile illness and systemic vasculitis of unknown aetiology that predominan

91 Wegener's granulomatosis (WG) is a systemic vasculitis of unknown etiology.

92 upus erythematosus (SLE) and 4 patients with systemic vasculitis on the expression of adhesion molecu

93 bsence of clinical or laboratory evidence of systemic vasculitis or a condition predisposing to such,

94 sitive SLE patients and 3 of 3 AECA-positive systemic vasculitis patients up-regulated adhesion molec

95 Giant cell arteritis (GCA) is a systemic vasculitis preferentially affecting large and m

96 ng non-systemic vasculitic neuropathy have a systemic vasculitis presenting with neuropathy; in other

97 of disease activity in children with primary systemic vasculitis (PSV).

98 alignant hypertension, may signal underlying systemic vasculitis rather than isolated hypertensive da

99 27 SLE patients, three patients with systemic vasculitis, seven patients with arthritis, and

100 Systemic vasculitis should be further classified into on

101 erived from the largest genetic study of any systemic vasculitis, suggest a central role of CCR5-CCL3

102 interest in atherosclerosis, but less so in systemic vasculitis (SV).

103 by circulating cryoglobulin associated with systemic vasculitis symptoms.

104 uppressive treatments for conditions such as systemic vasculitis, systemic lupus erythematosus, or ma

105 Kawasaki disease (KD) is a systemic vasculitis that affects young children and can

106 Kawasaki disease, a systemic vasculitis that affects young children and can

107 hcet's disease (BD) is a chronic, relapsing, systemic vasculitis that can involve both arteries and v

108 l arteritis (GCA) is the most common form of systemic vasculitis that causes visual loss in the elder

109 he rate of renal recovery in ANCA-associated systemic vasculitis that presented with renal failure wh

110 For 100 surviving patients with systemic vasculitis, the median VDI score at last observ

111 ally based assessment of disease activity in systemic vasculitis, the Vasculitis Integrated Assessmen

112 icroparticle (PMP) profiles in children with systemic vasculitis to test the hypothesis that EMPs may

113 e 1990 ACR criteria and CHCC definitions for systemic vasculitis were applied to an unselected cohort

114 of tolerance to neutrophil components during systemic vasculitis, which is marked by autoantibodies a

115 Behcet disease (BD) is a systemic vasculitis with a broad range of organ involvem

116 lomatosis with polyangiitis (EGPA) is a rare systemic vasculitis with a prevalence rate of seven per

117 Behcet syndrome is a systemic vasculitis with an unknown aetiology affecting